Capricor Therapeutics: A High Risk/High Reward Name
Summarize this article with:
Bret JensenInvesting Group LeaderFollow5ShareSavePlay(13min)CommentsSummaryCapricor Therapeutics recently more than tripled on positive Phase 3 HOPE-3 data for deramiocel in Duchenne muscular dystrophy cardiomyopathy.The company's Deramiocel showed a 54% slowing in upper limb deterioration and a 91% slowing in LVEF decline, supporting a strong case for FDA approval in 2026.CAPR secured lucrative U.S. and Japan partnerships, with up to $605M in milestones and 30–50% U.S. revenue share, plus a recent $161.9M capital raise.An analysis around Capricor Therapeutics follows in the paragraphs below.Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate. Learn More » MadamLead/iStock via Getty Images Shares of Duchenne muscular dystrophy concern Capricor Therapeutics, Inc. (CAPR) more than tripled on December 3, 2025 after releasing seemingly approvable Phase 3 disease progression data. The HOPE-3 results, including a 54% slowing of upper limb performance deterioration versusThis article was written byBret Jensen55.61K FollowersFollowBret Jensen has over 13 years as a market analyst, helping investors find big winners in the biotech sector. Bret specializes in high beta sectors with potentially large investor returns.Bret leads the investing group The Biotech Forum, in which he and his team offer a model portfolio with their favorite 12-20 high upside biotech stocks, live chat to discuss trade ideas, and weekly research and option trades. The group also provides market commentary and a portfolio update every weekend. Learn More.Analyst’s Disclosure:I/we have a beneficial long position in the shares of CAPR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.